SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) completed enrollment in its APOLLO trial to evaluate the safety and feasibility of adipose tissue-derived stem and regenerative cells, processed with the Company’s Celution® System, in the treatment of severe heart attacks. The steering committee deemed, in concurrence with data safety and monitoring board (DSMB), that the safety and feasibility goal in APOLLO was met at the initial cell dose and that the procedure did not raise safety concerns. Furthermore the steering committee recommended that a pivotal study be conducted to further evaluate efficacy. The DSMB has indicated their willingness to work with the steering committee to plan and execute this pivotal study. Cytori plans to report results on the primary six month follow up period for the APOLLO trial in late 2009.
